Viking Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -87 | |||
EBITDA | -74,574 | -55,469 | -46,128 | -36,556 |
EBIT | -46,238 | -36,643 | ||
Net Income | -65,561 | -45,629 | -35,417 | -24,940 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -47,061 | -52,331 | -31,181 | -21,962 |
Cash | 33,880 | 37,940 | 26,676 | 50,347 |
Basic Shares | 112,134 | 112,069 | 111,344 | 110,911 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $10 |
Gross Profit | -292 | -291 | -296 | |
EBITDA | -109,523 | -100,827 | -70,355 | -55,393 |
EBIT | -100,827 | -70,646 | -55,689 | |
Net Income | -109,963 | -85,895 | -67,379 | -54,002 |
Net Change In Cash | 0 | 0 | 0 | 10 |
Cost of Revenue | 10,519 | -2,746 | ||
Free Cash Flow | -87,790 | -73,376 | -48,397 | -47,586 |
Cash | 26,676 | 55,516 | 36,632 | 26,371 |
Basic Shares | 109,037 | 94,347 | 76,834 | 77,197 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.58 |
2025-03-31 | -$0.41 |
2024-12-31 | -$0.32 |
